Quest Partners LLC Has $849,000 Stock Position in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Quest Partners LLC grew its position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 2,582.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,774 shares of the company's stock after buying an additional 11,335 shares during the quarter. Quest Partners LLC's holdings in Prestige Consumer Healthcare were worth $849,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Natixis Advisors LLC boosted its holdings in shares of Prestige Consumer Healthcare by 11.4% during the 3rd quarter. Natixis Advisors LLC now owns 14,581 shares of the company's stock valued at $1,051,000 after purchasing an additional 1,491 shares during the last quarter. Huntington National Bank increased its position in shares of Prestige Consumer Healthcare by 39.9% during the third quarter. Huntington National Bank now owns 635 shares of the company's stock worth $46,000 after acquiring an additional 181 shares during the period. MQS Management LLC purchased a new position in shares of Prestige Consumer Healthcare during the third quarter worth approximately $552,000. Aigen Investment Management LP purchased a new position in Prestige Consumer Healthcare during the third quarter valued at approximately $345,000. Finally, Meritage Portfolio Management increased its holdings in Prestige Consumer Healthcare by 11.0% during the third quarter. Meritage Portfolio Management now owns 11,992 shares of the company's stock valued at $865,000 after buying an additional 1,193 shares during the period. 99.95% of the stock is currently owned by hedge funds and other institutional investors.

Prestige Consumer Healthcare Trading Up 0.8 %

NYSE:PBH traded up $0.71 on Friday, hitting $84.85. The stock had a trading volume of 273,597 shares, compared to its average volume of 251,712. The company has a fifty day moving average price of $74.13 and a two-hundred day moving average price of $70.57. The company has a quick ratio of 2.10, a current ratio of 3.56 and a debt-to-equity ratio of 0.61. Prestige Consumer Healthcare Inc. has a 1-year low of $56.61 and a 1-year high of $85.22. The stock has a market cap of $4.19 billion, a price-to-earnings ratio of 20.46, a PEG ratio of 2.32 and a beta of 0.47.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported $1.09 EPS for the quarter, meeting analysts' consensus estimates of $1.09. The company had revenue of $283.79 million for the quarter, compared to analyst estimates of $282.09 million. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. Prestige Consumer Healthcare's quarterly revenue was down .9% on a year-over-year basis. During the same period in the previous year, the business posted $1.07 earnings per share. Equities research analysts expect that Prestige Consumer Healthcare Inc. will post 4.45 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have issued reports on PBH. DA Davidson reaffirmed a "buy" rating and issued a $95.00 price target on shares of Prestige Consumer Healthcare in a report on Monday, November 11th. Jefferies Financial Group restated a "hold" rating and set a $76.00 target price (up from $70.00) on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 24th. One analyst has rated the stock with a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $83.67.

Insider Activity

In other Prestige Consumer Healthcare news, CEO Ronald M. Lombardi sold 10,875 shares of the stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $82.60, for a total transaction of $898,275.00. Following the sale, the chief executive officer now directly owns 320,952 shares of the company's stock, valued at approximately $26,510,635.20. This represents a 3.28 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Mary Beth Fritz sold 9,885 shares of the stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $81.97, for a total transaction of $810,273.45. Following the completion of the sale, the senior vice president now directly owns 18,835 shares in the company, valued at approximately $1,543,904.95. This trade represents a 34.42 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 38,810 shares of company stock valued at $3,187,300 over the last 90 days. Insiders own 1.60% of the company's stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.